250 related articles for article (PubMed ID: 26204517)
1. Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials.
Xing M; Yan F; Yu S; Shen P
PLoS One; 2015; 10(7):e0133569. PubMed ID: 26204517
[TBL] [Abstract][Full Text] [Related]
2. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
Gibson JM; Alzghari S; Ahn C; Trantham H; La-Beck NM
Oncologist; 2013; 18(9):1022-31. PubMed ID: 23881990
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Gil-Gil MJ; Bellet M; Morales S; Ojeda B; Manso L; Mesia C; Garcia-Martínez E; Martinez-Jáñez N; Melé M; Llombart A; Pernas S; Villagrasa P; Blasco C; Baselga J
Breast Cancer Res Treat; 2015 Jun; 151(3):597-606. PubMed ID: 25981896
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
[TBL] [Abstract][Full Text] [Related]
6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
11. The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy: A systematic review and meta-analysis.
Zhang KP; Fang X; Zhang Y; Chao M
Medicine (Baltimore); 2021 Aug; 100(34):e26690. PubMed ID: 34449454
[TBL] [Abstract][Full Text] [Related]
12. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
13. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
[TBL] [Abstract][Full Text] [Related]
14. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
15. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S; Scambia G; Savarese A; Breda E; Scollo P; De Vivo R; Rossi E; Gebbia V; Natale D; Del Gaizo F; Naglieri E; Ferro A; Musso P; D'Arco AM; Sorio R; Pisano C; Di Maio M; Signoriello G; Annunziata A; Perrone F;
BMC Cancer; 2006 Aug; 6():202. PubMed ID: 16882344
[TBL] [Abstract][Full Text] [Related]
16. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Elgebaly A; Menshawy A; El Ashal G; Osama O; Ghanem E; Omar A; Negida A
Breast Dis; 2016 Jul; 36(2-3):91-101. PubMed ID: 27612040
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.
Stavridi F; Palmieri C
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1859-69. PubMed ID: 19046106
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Mao Z; Shen K; Zhu L; Xu M; Yu F; Xue D; Li H; Xue C
Oncol Res Treat; 2019; 42(7-8):405-413. PubMed ID: 31104059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]